BR112021011728A8 - Antagonista do receptor de estrogênio - Google Patents

Antagonista do receptor de estrogênio

Info

Publication number
BR112021011728A8
BR112021011728A8 BR112021011728A BR112021011728A BR112021011728A8 BR 112021011728 A8 BR112021011728 A8 BR 112021011728A8 BR 112021011728 A BR112021011728 A BR 112021011728A BR 112021011728 A BR112021011728 A BR 112021011728A BR 112021011728 A8 BR112021011728 A8 BR 112021011728A8
Authority
BR
Brazil
Prior art keywords
estrogen receptor
receptor antagonist
estrogen
isomer
drug
Prior art date
Application number
BR112021011728A
Other languages
English (en)
Other versions
BR112021011728A2 (pt
Inventor
Duan Shuwen
Lu Jianyu
Hu Lihong
Z Ding Charles
Hu Guoping
Li Jian
Chen Shuhui
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd, Medshine Discovery Inc filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of BR112021011728A2 publication Critical patent/BR112021011728A2/pt
Publication of BR112021011728A8 publication Critical patent/BR112021011728A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

ANTAGONISTA DO RECEPTOR DE ESTROGÊNIO. A presente invenção refere-se a um composto de indol. Em particular, são divulgados um composto representado pela fórmula (II) ou um isômero ou sal farmaceuticamente aceitável do mesmo e um uso do mesmo como um antagonista do receptor de estrogênio na preparação de uma droga para o tratamento de câncer de mama positivo para receptor de estrogênio.
BR112021011728A 2018-12-17 2019-12-17 Antagonista do receptor de estrogênio BR112021011728A8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN201811545117 2018-12-17
CN201811545117.2 2018-12-17
CN201910611070 2019-07-08
CN201910611070.3 2019-07-08
CN201910877339 2019-09-17
CN201910877339.2 2019-09-17
PCT/CN2019/126046 WO2020125640A1 (zh) 2018-12-17 2019-12-17 雌激素受体拮抗剂

Publications (2)

Publication Number Publication Date
BR112021011728A2 BR112021011728A2 (pt) 2021-08-31
BR112021011728A8 true BR112021011728A8 (pt) 2023-01-31

Family

ID=71100660

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021011728A BR112021011728A8 (pt) 2018-12-17 2019-12-17 Antagonista do receptor de estrogênio

Country Status (12)

Country Link
US (1) US20220033376A1 (pt)
EP (1) EP3889133A4 (pt)
JP (1) JP2022513942A (pt)
KR (1) KR20210105384A (pt)
CN (2) CN117430585A (pt)
AU (1) AU2019400398A1 (pt)
BR (1) BR112021011728A8 (pt)
CA (1) CA3122621A1 (pt)
MX (1) MX2021007088A (pt)
PH (1) PH12021551437A1 (pt)
SG (1) SG11202106401UA (pt)
WO (1) WO2020125640A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240043401A1 (en) 2020-12-30 2024-02-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Salt form of tetra-substituted olefin compound, crystal, and preparation method therefor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2483736B (en) * 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
SG11201405918XA (en) * 2012-03-20 2014-10-30 Seragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
KR102664618B1 (ko) * 2015-05-29 2024-05-10 에자이 알앤드디 매니지먼트 가부시키가이샤 사치환된 알켄 화합물 및 그의 용도
WO2016196342A1 (en) * 2015-05-29 2016-12-08 Eisai R&D Management Co., Ltd. Tetrasubstituted alkene compounds and their use
AU2017239348B2 (en) * 2016-03-25 2020-03-12 Luoxin Healthcare Science and Technology Development (Beijing) Ltd. Substituted-indole compounds as estrogen receptor down-regulators
US20190337921A1 (en) * 2016-11-24 2019-11-07 Eisai R&D Management Co., Ltd. Tetrasubstituted alkene compounds and their use

Also Published As

Publication number Publication date
WO2020125640A1 (zh) 2020-06-25
KR20210105384A (ko) 2021-08-26
AU2019400398A1 (en) 2021-07-15
JP2022513942A (ja) 2022-02-09
CA3122621A1 (en) 2020-06-25
EP3889133A1 (en) 2021-10-06
MX2021007088A (es) 2021-09-08
PH12021551437A1 (en) 2021-12-06
SG11202106401UA (en) 2021-07-29
CN113166055B (zh) 2023-09-08
CN117430585A (zh) 2024-01-23
US20220033376A1 (en) 2022-02-03
CN113166055A (zh) 2021-07-23
BR112021011728A2 (pt) 2021-08-31
EP3889133A4 (en) 2022-09-07

Similar Documents

Publication Publication Date Title
NZ747259A (en) Soluble c5ar antagonists
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
DOP2019000201A (es) Compuestos inhibidores del vih
CL2015001508A1 (es) Compuestos derivados de bencimidazol, antagonistas de receptores ep4; composicion farmaceutica; combinacion farmaceutica; uso para tratar y/o prevenir enfermedades tales como endometriosis, hemorragias uterinas, dismenorrea, canceres de pulmon, de intestino, de mama, de prostata, entre otros.
EA201792515A1 (ru) ЗАМЕЩЕННЫЕ СОЕДИНЕНИЯ ТЕТРАГИДРОХИНОЛИНОНА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕТИНОИДНЫХ ОРФАНОВЫХ РЕЦЕПТОРОВ ГАММА (RORγ)
BR112018015419A2 (pt) degradantes seletivos de receptor de estrogênio e os usos dos mesmos
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
BR112016010080A8 (pt) compostos de pirazolopirimidina, composição farmacêutica e seu uso
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
BR112012027743A2 (pt) ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
MX2013008431A (es) Antagonista del receptor de mineralocorticoides.
BR112014016635B8 (pt) composto, composição, e, uso de um composto
MX2016007128A (es) Compuestos del receptor 6 de quimiocina (ccr6).
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
SA520411635B1 (ar) A2a مشتق حلقي مدمج كمثبط مستقبل
EA202091262A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
PH12021550048A1 (en) Selective estrogen receptor degraders.
CY1122731T1 (el) Διαμορφωτες υποδοχεα οιστρογονων
BR112019002560A2 (pt) composto, composição farmacêutica, uso de um composto, e, método
EA201692298A1 (ru) Производные карбоксамидов
EA201891682A1 (ru) Производное азациклического амида, способ его получения и фармацевтическое применение
MY176521A (en) Pyrrole-substituted indolone derivative, preparation method therefor, composition comprising the same and use thereof
MX2021007687A (es) Sales novedosas de degradadores selectivos de receptores de estrogeno.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD (CN)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]